World's Best Scientists 2026 revealed!
Jeffrey Crawford

Jeffrey Crawford

D-Index & Metrics

Medicine

D-Index
84
Citations
32083
World Ranking
14927
National Ranking
7545

Overview

Jeffrey Crawford is affiliated with Duke University in the United States and has contributed extensively to the field of medicine, focusing primarily on oncology. Their research encompasses a broad spectrum of topics related to cancer treatment and patient care, with a particular emphasis on chemotherapy effects, lung cancer, and biomarkers associated with cancer progression and cachexia.

Their publication record includes significant papers such as:

  • Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis (2021, The Oncologist)
  • Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? (2022, The Oncologist)
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (2021, Journal for ImmunoTherapy of Cancer)
  • A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia (2023, Clinical Cancer Research)
  • Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life (2021, Patient Preference and Adherence)

Crawford's frequent co-authors include Jeffrey Clarke, Michelle I. Rossulek, Thomas E. Stinchcombe, Richard F. Dunne, and Scott Antonia, reflecting collaborative work predominantly in oncology-related studies.

The primary venues for their publications are:

  • Journal of Clinical Oncology
  • Journal of Cachexia Sarcopenia and Muscle
  • The Oncologist
  • Supportive Care in Cancer
  • Lung Cancer

Their main field of study is medicine, with subfields concentrating on:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Physiology
  • Genetics
  • Molecular Biology

Within these fields, Crawford's research addresses topics such as:

  • Neutropenia and Cancer Infections
  • Nutrition and Health in Aging
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Lung Cancer Research Studies
  • GDF15 and Related Biomarkers
  • Cancer Immunotherapy and Biomarkers

Their work notably explores clinical challenges in managing chemotherapy-induced side effects like neutropenia and myelosuppression, as well as investigating therapeutic approaches to lung cancer resistant to immune checkpoint inhibitors. Another area of focus involves cancer cachexia and associated biomarkers, contributing to understanding pathological mechanisms and treatment strategies.

Best Publications

  • Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

    Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford

  • Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

    Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson

  • 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

    Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer

  • 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*

    Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer

  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : A systematic review

    Nicole M. Kuderer;David C. Dale;Jeffrey Crawford;Gary H. Lyman

  • Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

    Thomas J. Smith;Kari Bohlke;Gary H. Lyman;Kenneth R. Carson

  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

    B J Roth;D H Johnson;L H Einhorn;L P Schacter

  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

    Matti Aapro;David A Cameron;Ruth Pettengell;Julia Bohlius

  • Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices

    Gary H. Lyman;David C. Dale;Jeffrey Crawford

  • Sarcopenia: A Time for Action. An SCWD Position Paper.

    Juergen Bauer;John E. Morley;Annemie M.W.J. Schols;Luigi Ferrucci

  • Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

    Jeffrey Crawford;David Cella;Charles S. Cleeland;Pierre Yves Cremieux;Pierre Yves Cremieux

  • Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431

    Everett E. Vokes;James E. Herndon;Jeffrey Crawford;Kenneth A. Leopold

  • Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

    Gary H. Lyman;David C. Dale;Jonathan Friedberg;Jeffrey Crawford

  • Effects of Polyethylene Glycol–Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts after Chemotherapy for Lung Cancer

    Michael Fanucchi;John Glaspy;Jeffrey Crawford;Jennifer Garst

  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

    Eileen Johnston;Jeffrey Crawford;Susan Blackwell;Toni Bjurstrom

  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

    R.N. Patricia J. Hollen Ph.D.;Richard J. Gralla;Mark G. Kris;Christopher Cox

  • Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

    Pasi A. Jänne;Xiaofei Wang;Mark A. Socinski;Jeffrey Crawford

  • Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

    Kenneth A. Foon;Xiao Dong Yang;Louis M. Weiner;Arie S. Belldegrun

  • Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

    J Glaspy;J Crawford;Johan Vansteenkiste;D Henry

  • Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy

    Gary H. Lyman;Vicki A. Morrison;David C. Dale;Jeffrey Crawford

Frequent Co-Authors

Gary H. Lyman
Gary H. Lyman Fred Hutchinson Cancer Research Center
David C. Dale
David C. Dale University of Washington
James E. Herndon
James E. Herndon Duke University
John A. Glaspy
John A. Glaspy University of California, Los Angeles
Harvey J. Cohen
Harvey J. Cohen Duke University
Everett E. Vokes
Everett E. Vokes University of Chicago
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Thomas A. D'Amico
Thomas A. D'Amico Duke University
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a medical degree is a rewarding path, there are several related online programs that can expand your career opportunities in healthcare. Many students consider obtaining a masters in healthcare administration cost degree to move into leadership and management roles within hospitals and clinics. This degree equips you with financial, operational, and strategic skills crucial for modern healthcare systems.

For nurses seeking to advance their clinical expertise or assume higher responsibilities, exploring the best dnp programs online can be an excellent next step. Doctor of Nursing Practice (DNP) degrees are ideal for those interested in advanced practice, leadership, or specialized research roles.

The pharmaceutical field is another fast-growing industry. Accredited online pharmacy programs are designed for those aspiring to become pharmacists without the limitations of on-campus programs, providing flexibility and affordability.

With healthcare technology evolving rapidly, a bachelor of health information management online opens doors to careers in data management, informatics, and health IT. These roles are critical to ensuring patient information is secure, accurate, and efficiently managed.

Best Scientists Citing Jeffrey Crawford

Trending Scientists

Recently Published Articles